Overall, these data suggest that pre-existing adaptive immunity as measured at the tumor level by CD8 T cell infiltration and their spatial distribution as well as PD-L1 expression may be required to predict clinical response to anti-PD-L1 inhibitors. The gene discussed is CD274; the disease is neoplasm.